Want to take quizzes and track your credits?
With more than 40 million cases of confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection worldwide, the clinical presentation and risk factors for disease severity among adults and children have now been well described.1 SARS-CoV-2 is the virus that causes coronavirus disease 2019. However, little remains known about disease manifestation and severity of illness in infants.2 Although infants are at higher risk of severe disease and complications from other common viral respiratory pathogens (influenza, respiratory syncytial virus), it is not yet clear whether this is the case with SARS-CoV-2 infection because few series describing outcomes in infants have been published.3,4 The objective of this study was to describe the manifestations and severity of disease among infants with SARS-CoV-2 infection.
Sign in to take quiz and track your certificates
CME Disclosure Statement: Unless noted, all individuals in control of content reported no relevant financial relationships. If applicable, all relevant financial relationships have been mitigated.
Accepted for Publication: October 21, 2020.
Published: December 14, 2020. doi:10.1001/jamanetworkopen.2020.30470
Correction: This article was corrected on February 5, 2021, to fix the spelling of the third author’s first name in the byline.
Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2020 Panetta L et al. JAMA Network Open.
Corresponding Author: Fatima Kakkar, MD, MPH, Division of Infectious Disease, Department of Pediatrics, Centre Hospitalier Universitaire Sainte-Justine, 3175 Chemin de la Côte-Sainte-Catherine, Montreal, QC H3T 1C5, Canada (email@example.com).
Author Contributions: Drs Kakkar and Panetta had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Panetta, Proulx, Autmizguine, Luu, Kakkar.
Acquisition, analysis, or interpretation of data: Panetta, Proulx, Drouin, Autmizguine, Quach, Kakkar.
Drafting of the manuscript: Panetta, Kakkar.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: Kakkar.
Obtained funding: Kakkar.
Administrative, technical, or material support: Panetta, Luu, Quach.
Supervision: Drouin, Kakkar.
Conflict of Interest Disclosures: None reported.
Funding/Support: This work was supported by a Réseau SIDA Maladies Infectieuses coronavirus disease 2019 COVID-19 grant to Dr Kakkar that provided funding for the design and conduct of the study, data collection and, management. Drs Kakkar, Drouin, Luu, Autmizgine, and Quach are supported by Fonds de Recherche Santé clinician investigator grants that provide salary support for protected time that allowed for data analysis and manuscript preparation.
Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and the decision to submit the manuscript for publication.
Additional Contributions: The authors thank all members of the CHU-Sainte Justine COVID-19 response team, including the COVID-19 outpatient clinic team leader (Geneviève Parisien, BSc), infection control prevention team (Nadia Demarais, RN, and Gaelle Anick Delisle, MSc), pediatric infectious diseases team (Bruce Tapiero, MD, Valerie Lamarre, MD, Philippe Ovetchkine, MD, Marc Lebel, MD, Chantal Buteau MD, and Ana Blanchard, MD, MSc), medical microbiology team (Christian Renaud MD, MSc, Emilie Valières MD, PhD, and Julie Blackburn, MD), and research team of the Centre d’Infectiologie Mère-enfant (Silvie Valois RN, and Suzanne Taillefer, PhD) for their work in rapidly establishing the clinical and research infrastructures needed to address the COVID-19 pandemic at CHU-Sainte-Justine.
You currently have no searches saved.
You currently have no courses saved.